



#2

PATENT

0400

BOXSEQ

Case Docket No.: UC067.004A
Date: January 25, 2002

1/30/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s) : SAXON

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in an
envelope addressed to: Commissioner for Patents,
Washington, D.C. 20231, on

Appl. No. : 10/000,439

January 25, 2002
(Date)

Filed : October 24, 2001


Ginger R. Dreger, Registration No. 33,055For : FUSION MOLECULES AND
METHODS FOR
TREATMENT OF IMMUNE
DISEASES

Examiner : Unknown

Group Art Unit : Unknown


TRANSMITTAL LETTER

**COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231**

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A Form PTO-1449 with copies of 115 references.
- (X) Sequence Submission Statement.
- (X) Sequence Listing in paper format.
- (X) Sequence Listing in computer readable format.
- (X) The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Ginger R. Dreger
Registration No. 33,055
Attorney of Record

UC067.004A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	SAXON) Group Art Unit: Unknown
)
App. No.	:	10/000,439)
)
Filed	:	October 24, 2001)
)
For	:	FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES)
)
Examiner	:	Unknown)
)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing 115 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 25, 2002

By: Ginger R. Dreger

Ginger R. Dreger

Registration No. 33,055

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(415) 954-4114

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
		APPLICANT Saxon	
		FILING DATE October 24, 2001	GROUP Not yet assigned

FEB 12 2002
P A T E N T & T R A D E M A R K O F F I C E

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1.	5,329,028	07/12/94	Ashkenazi et al.	548	548	08/05/92
2.	5,336,603 A	08/09/94	Capon et al.	435	69.7	08/26/92
3.	5,925,351	07/20/99	Browning et al.	424	143.1	07/21/95

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
4.	WO88/09344	01.12.88	PCT				
5.	WO96/26961	06.09.96	PCT				
6.	WO96/40789	19.12.96	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
7.	Adamczewski, M., and Kinet, J-P., "The High-Affinity Receptor for Immunoglobulin E," <u>Chemical Immun.</u> , 59:173-190 (1994).
8.	Antoniou, A. N. et al., "Control of Antigen Presentation by a Single Protease Cleavage Site," <u>Immunity</u> , 12(4):391-398, (2000).
9.	Arm, J. P. et al., "Molecular Cloning of gp49, a Cell-surface Antigen That Is Preferentially Expressed by Mouse Mast Cell Progenitors and Is a New Member of the Immunoglobulin Superfamily" <u>J. Biol. Chem.</u> 266:15966-15973 (1991).
10.	Arm, J. P. et al., "Molecular Identification of a Novel Family of Human Ig Superfamily Members That Possess Immunoreceptor Tyrosine-Based Inhibition Motifs and Homology to the Mouse gp49B1 Inhibitory Receptor," <u>J. Immunol.</u> , 159:2342-2349 (1997).
11.	Ashman, R. F. et al., "Fc Receptor Off-Signal in the B Cell Involves Apoptosis," 157:5-11 (1996).
12.	Barnes, P. J., "Anti-IgE Antibody Therapy for Asthma," <u>The New England Journal of Medicine</u> 341(26):2006-2008 (1999).
13.	Basu, M. et al., "Purification and Characterization of Human Recombinant IgE-Fc Fragments That Bind to the Human High Affinity IgE Receptor," <u>J. Biol. Chem.</u> , 268(18):13118-13127 (June 1993).
14.	Beasley, R. et al., "Prevalence and etiology of asthma," <u>J. Allergy Clin. Immunol.</u> 105(2)(Part 2):S466-S472 (2000).
15.	Bellmann, K. et al., "Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats," <u>Diabetologia</u> 41:844-847 (1998).
16.	Blanas, E. et al., "Induction of Autoimmune Diabetes by Oral Administration of Autoantigen," <u>Science</u> 274:1707-1709 (1996).
17.	Blondel, A. et al., "Engineering the quaternary structure of an exported protein with a leucine zipper," <u>Protein Engineering</u> , 4(4):457-461 (1991).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT (USE SEVERAL SHEETS IF NECESSARY) FEB 12 2002	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
EXAMINER Saxon		
APPLICANT		
FILING DATE October 24, 2001	GROUP Not yet assigned	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
18.	Breitender, H. et al., "Complementary DNA cloning and expression in <i>Escherichia coli</i> of <i>Aln g 1</i> , the major allergen in pollen of alder (<i>Alnus glutinosa</i>), <i>J. Allergy Clin. Immunol.</i> 90(6)(Part 1):909-917 (1992).
19.	Burks, A. W. et al., "Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin and a major allergen in peanut hypersensitivity," <i>Eur. J. Biochem.</i> , 245:334-339 (1997).
20.	Cambier, J. C., "Inhibitory receptors abound?" <i>Proc. Natl. Acad. Sci. USA</i> , 94:5993-5995 (1997).
21.	Casares, S. et al. "Engineering and characterization of a murine MGC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope" <i>Protein Engineering</i> 10(11):1295-1301 (1997)
22.	Casares, S. et al., "Antigen-specific Signaling by a Soluble, Dimeric Peptide/Major Histocompatibility Complex Class II/Fc Chimera Leading to T helper Cell Type 2 Differentiation," <i>J. Exp. Med.</i> , 190:543-553 (November 1999).
23.	Chaillous, L. et al., "Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial," <i>Lancet</i> , 356:545-549 (2000).
24.	Chan, P. L. et al., "Regulation of the Immune Response," <i>Immunology</i> , 21:967-981 (1971).
25.	Costa, M. A. et al., "The IgE-binding epitopes of rPar j 2, a major allergen of <i>Parietaria judaica</i> pollen, are heterogeneously recognized among allergic subjects," <i>Allergy</i> 55:246-250 (2000).
26.	Daëron, M. et al., "Regulation of High-affinity IgE Receptor-mediated Mast Cell Activation by Murine Low-affinity IgG Receptors.", <i>J. Clin. Invest.</i> , 95:577-585 (February 1995).
27.	Daëron, M. et al., "The Same Tyrosine-Based Inhibition Motif, in the Intra-cytoplasmic Domain of FCyRIIB, Regulates Negatively BCR-, TCR-, and FcR-Dependent Cell Activation," <i>Immunity</i> , 3:635-646 (November 1995).
28.	Daëron, M., "Fc Receptor Biology," <i>Annu. Rev. Immunol.</i> , 15:203-234 (1997).
29.	Davidson, A. et al., "Autoimmune Diseases," <i>N. Engl. J. Med.</i> , 345(5):340-350 (2001).
30.	De Lara, J.M. Tunon, "Immunoglobulines E et cellules de l'inflammation," <i>Rev. Mal. Resp.</i> , 13:27-36 (1996).
31.	Ellison J. et al., "Linkage and sequence homology of two human immunoglobulin γ heavy chain constant region genes," <i>Proc. Nat. Acad. Sci. USA</i> , 79:1984-1988 (1982).
32.	Ellison J. W. et al., "The nucleotide sequence of a human immunoglobulin cy1 gene" <i>Nucl. Acids Res.</i> , 10(13):4071-4079 (1982).
33.	Fiebiger, E. et al., "Anti-FcεRIα Autoantibodies in Autoimmune-mediated Disorders. Identification of a Structure-Function Relationship," <i>J. Clin. Invest.</i> 101:243-251 (January 1998).
34.	Fiebiger, E. et al., "Serum IgG Autoantibodies Directed against the α Chain of Fcε RI: A Selective Marker and Pathogenic Factor for a Distinct Subset of Chronic Urticaria Patients?" <i>The Journal of Clinical Investigation</i> 96:2606-2612 (December 1995).
35.	Fridman, W. H., "Fc receptors and immunoglobulin binding factors," <i>FASEB J.</i> , 5(12):2684-2690 (1991).
36.	Gale, E. AM, "Oral tolerance and autoimmune diabetes – will hope triumph over experience?" <i>Lancet</i> 356 (9229):526-527 (2000).
37.	Genain, C. P. et al., "Late Complications of Immune Deviation Therapy in a Nonhuman Primate," <i>Science</i> 274:2054-2057 (1996).
38.	Gerber J. S. et al. "Reversing Lipopolysaccharide Toxicity by Ligating the Macrophage Fcγ Receptors," <i>The Journal of Immunology</i> , 166:6861-6868 (2001).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) FEB 12 2002	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
	APPLICANT Saxon	
	FILING DATE October 24, 2001	GROUP Not yet assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
39.	Gollnick, S. O. et al., "Isolation, Characterization, and Expression of cDNA Clones Encoding the Mouse Fc Receptor for IgE (Fc ϵ RII)" <u>The Journal of Immunology</u> 144(5):1974-1982 (1974).
40.	Goodkin, D. E. et al., "A phase I trial of solubilized DR2:MBP ⁸⁴⁻¹⁰² (AG284) in multiple sclerosis," <u>Neurology</u> 54:1414-1420 (2000).
41.	Harrison, L. C. et al., "Antigen-specific therapy for autoimmune disease," <u>Curr. Opin. Immunol.</u> , 12:704-711 (2000).
42.	Haselden, B. M. et al., "Immunoglobulin E-independent Major Histocompatibility Complex-restricted T Cell Peptide Epitope-induced Late Asthmatic Reactions," <u>J. Exp. Med.</u> , 189(12):1885-1894 (1999).
43.	Hayami, K. et al., "Molecular Cloning of a Novel Murine Cell-surface Glycoprotein Homologous to Killer Cell Inhibitory Receptors," <u>J. Biol. Chem.</u> , 272(11):7320-7327 (1997).
44.	Hellman, L., "Characterization of four novel ϵ chain of mRNA and a comparative analysis of genes for immunoglobulin E in rodents and man," <u>Eur. J. Immunol.</u> 23:159-167 (1993).
45.	Helm, B. A. et al., "Identification of the High Affinity Receptor Binding Region in Human Immunoglobulin E," <u>J. Biol. Chem.</u> , 271(13):7494-7500 (1996).
46.	Hide, M. et al., "Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria," <u>N. Engl. J. Med.</u> , 328:1599-1604 (1993).
47.	Kabat, <u>Sequences of Proteins of Immunological Interest</u> , Vol. III Fifth Ed. (1991).
48.	Kaplan, A. P., "Urticaria and Angioedema," <u>Inflammation: Basic Principles and Clinical Correlates</u> , (Gallin and Snyderman eds.), 3 rd Edition, Lippincott & Wilkins, Philadelphia, 1999, pp. 915-928.
49.	Katz, H. R., "gp49BE and Its Related Family of Counterregulatory Receptors of the Immunoglobulin Superfamily," <u>Int. Arch. Allergy Immunol.</u> , 118:177-179 (1999).
50.	Kepley, C. L., "Negative regulation of Fc ϵ RII signaling by FcgammaRII costimulation in human blood basophils," <u>J. Allergy Clin. Immunol.</u> , 106(2):337-348 (2000).
51.	Kikutani, H. et al., "Molecular Structure of Human Lymphocyte Receptor for Immunoglobulin E," <u>Cell</u> 47:657-665 (December 1986).
52.	Kinet, J-P, "The High-Affinity IgE Receptor (Fc ϵ RI): From Physiology to Pathology," <u>Annu. Rev. Immunol.</u> , 17:931-972 (1999).
53.	Kondo et al., "Cloning of CdnAs for New Subtypes of Murine Low-Affinity Fc Receptor for IgE (Fc ϵ RII/CG23)," <u>Int. Arch. Immunol.</u> , 105:38-48 (1994).
54.	Krauss, S. et al., "Recombinant CD4-IgE, a novel hybrid molecule, inducing basophils to respond to human immunodeficiency virus (HIV) and HIV-infected target cells," <u>Eur. J. Immunol.</u> , 25(1):192-199 (1995).
55.	Krawinkel, U. et al., "Comparison of the hinge-coding segments in human immunoglobulin gamma heavy chain genes and the linkage of the gamma 2 and gamma 4 subclass genes," <u>The EMBO Journal</u> , 1(4):403-407 (1982).
56.	Landschulz, W. H. et al., "The Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins," <u>Science</u> 240:1759-1764 (1988).
57.	Legge, K. L. et al., "Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing," <u>J. Exp. Med.</u> , 185(6):1043-1053 (March 1997).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>O'NEALE Saxon</i> (USE SEVERAL SHEETS IF NECESSARY) FEB 12 2002		APPLICANT Saxon	
		FILING DATE October 24, 2001	GROUP Not yet assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
	58. Legge, K. L. et al., "Coupling of Peripheral Tolerance to Endogenous Interleukin 10 Promotes Effective Modulation of Myelin-activated T Cells and Ameliorates Experimental Allergic Encephalomyelitis," <u>J. Exp. Med.</u> , 191(12):2039-2051 (June 2000).		
	59. Luckey et al., "Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors," <u>The Journal of Immunology</u> , 167:1212-1221 (2001).		
	60. Lüdin, C. et al., "Cloning and expression of the cDNA coding for a human lymphocyte IgE receptor," <u>The EMBO Journal</u> , 6(1):109-114 (1987).		
	61. Lu-Kuo, J. M. et al., "gp49B1 Inhibits IgE-initiated Mast Cell Activation through Both Immunoreceptor Tyrosine-based Inhibitory Motifs, Recruitment of src Homology 2 Domain-containing Phosphatase-1, and Suppression of Early and Late Calcium Mobilization," <u>J. Biol. Chem.</u> , 274(9):5791-5796 (1999).		
	62. Lyczak, J. B. et al., "Expression of Novel Secreted Isoforms of Human Immunoglobulin E Protein," <u>J. Biol. Chem.</u> , 271(7):3428-3436 (1996).		
	63. Malbec, O. et al., "Negative Regulation of Hematopoietic Cell Activation and Proliferation by Fc γ RIIB," <u>Curr. Top. Microbiol. Immunol.</u> , 244:13-27 (1999).		
	64. Max, E. E. et al., "Duplication and Deletion in the Human Immunoglobulin ϵ Genes," <u>Cell</u> 29:691-699 (June 1992).		
	65. Metcalfe, D. D. et al., "Mast Cells," <u>Physiological Reviews</u> , 77(4):1033-1079 (October 1997).		
	66. Mocci, S. et al., "The role of autoantigens in autoimmune disease," <u>Curr. Opin. Immunol.</u> , 12:725-730 (2000).		
	67. Moreland, L. W. et al., "T Cell Receptor Peptide Vaccination in Rheumatoid Arthritis," <u>Arthritis Rheum.</u> , 41(11):1919-1929 (1998).		
	68. Mustelin, T. et al., "Lymphocyte Activation: The coming of the protein tyrosine phosphatases," <u>Front. Biosci.</u> 3:d1060-1096 (1998).		
	69. Naquet, P. et al., "T Cell Autoreactivity to Insulin in Diabetic and Related Non-Diabetic Individuals," <u>J. Immunol.</u> , 140(8):2569-2578 (1988).		
	70. Nepom, G. T. et al., "Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (Hgad65)," <u>Proc. Natl. Acad. Sci. USA</u> , 98(4):1763-1768 (2001).		
	71. Ngo, J. T. et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , 1994, Merz et al., (eds.), Birkhauser, Boston, MA, pp. 433 and 492-495.		
	72. Oliver, J. M. et al., "Immunologically mediated signaling in basophils and mast cells: finding therapeutic targets for allergic diseases in the human Fc ϵ R1 signaling pathway," <u>Immunopharmacology</u> , 48:269-281 (2000).		
	73. O'Shea, E. K. et al., "Evidence That the Leucine Zipper Is a Coiled Coil," <u>Science</u> , 243: 538-542 (1989).		
	74. Ota, K. et al., "T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis," <u>Nature</u> , 346:183-187 (1990).		
	75. Ott, V. L. et al., "Activating and inhibitory signaling in mast cells: New opportunities for therapeutic intervention?" <u>J. Allergy Clin. Immunol.</u> , 106(3):429-440 (2000).		
	76. Peat, J. K. et al., "Reversing the trend: Reducing the prevalence of asthma," <u>J. Allergy Clin. Immunol.</u> , 103(1)(Part 1):1-10 (1999)		

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>OTPE</i> (USE SEVERAL SHEETS IF NECESSARY) FEB 12 2002	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
		APPLICANT Saxon	
		FILING DATE October 24, 2001	GROUP Not yet assigned

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
77.	Peng, C. et al., "A New Isoform of Human Membrane-Bound IgE," <u>The Journal of Immunology</u> , 148(1):129-136 (January 1992).
78.	Pozzilli, P. et al., "No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII)," <u>Diabetologia</u> , 43:1000-1004 (2000).
79.	Presta, L. et al., "The Binding Site on Human Immunoglobulin E for Its High Affinity Receptor," <u>J. Biol. Chem.</u> , 269(42):26368-26373 (1994).
80.	Rabjohn, P. et al., "Molecular cloning and epitope analysis of the peanut allergen Ara h 3," <u>J. Clin. Invest.</u> , 103(4):535-542 (1999).
81.	Rock, K. L. et al., "Degradation of cell proteins and the generation of MHC class I-presented peptides," <u>Annu. Rev. Immunol.</u> , 17:739-779 (1999).
82.	Ruckert, R. et al., "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response <i>in vivo</i> , while IL-2-IgG2b fusion protein inhibits both," <u>Eur. J. Immunol.</u> , 28:3312-3320 (1998).
83.	Saxon, A. et al., "Inhibition of Human IgE Production Via FcεR-II Stimulation Results From a Decrease in the mRNA for Secreted But not Membrane ε H Chains," <u>The Journal of Immunology</u> , 147(11):4000-4006 (December 1991).
84.	Schmidt-Dorr, T. et al., "Construction , Purification, and Characterization of a Hybrid Protein Comprising the DNA Binding Domain of the LexA Repressor and the Jun Leucine Zipper: A Circular Dichroism and Mutagenesis Study", <u>Biochemistry</u> , 30:9657-9664 (1991).
85.	Sharma, S. D. et al., "Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes," <u>Proc. Natl. Acad. Sci. USA</u> , 88:11465-11469 (1991).
86.	Sinclair, N. R., "Why So Many Coinhibitory Receptors?" <u>Scand. J. Immunol.</u> , 50:10-13 (1999).
87.	Skolnick, J. et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech.</u> , 18(1):34-39 (Jan 2000).
88.	Slidregt, Leo A. J. M. et al., "Design and synthesis of a multivalent homing device for targeting to murine CD22," <u>Bioorganic & Medicinal Chemistry</u> , 9(1):85-97 (January 2001).
89.	Stanley, J. S. et al., "Identification and Mutational Analysis of the Immunodominant IgE Binding Epitopes of the Major Peanut Allergen Ara h 2," <u>Arch. Biochem. Biophys.</u> , 342(2):244-253 (1997).
90.	Steinman, L. et al., "Antigen Specific Immunotherapy of Multiple Sclerosis," <u>Jour. Clin. Immunol.</u> , 21(2):93-98 (2001).
91.	Stevenson, G. T. et al., "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'γ and Analogous Ligands," <u>J. Immunol.</u> , 158(5):2242-50 (March 1997).
92.	Sutterwala, F. S. et al., "Reversal of Proinflammatory Responses by Ligating the Macrophage Fcγ Receptor Type I," <u>J. Exp. Med.</u> , 188(1):217-222 (July 1998).
93.	Sutterwala, F. S. et al., "Selective Suppression of Interleukin-12 Induction after Macrophage Receptor Ligation," <u>J. Exp. Med.</u> , 185(11):1977-1985 (June 1997).
94.	Takahashi, N. et al., "Structure of Human Immunoglobulin Gamma Genes: Implications for Evolution of a Gene Family," <u>Cell</u> , 29:671-679 (1982).
95.	TePas, E. C. et al., "Immunotherapy of asthma and allergic diseases," <u>Curr. Opin. Pediatrics</u> , 12:574-578 (2000).
96.	van Rossenberg, S. M. W. et al., "A structure-function study of ligand recognition by CD22β," <u>J. Biol. Chem.</u> , 276(16):12967-12973 (2001).

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UC067.004A	APPLICATION NO. 10/000,439
		APPLICANT Saxon	
		FILING DATE October 24, 2001	GROUP Not yet assigned

O I P E
FEB 12 2002

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
97.	Varshavsky, A., "The N-End Rule," <u>Cell</u> , 69:725-735 (1992).
98.	Villadangos, J. A. et al., "Proteases involved in MHC class II antigen presentation," <u>Immunol. Rev.</u> , 172:109-120 (1999).
99.	Villadangos, J. A. et al., "Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?" <u>Immunity</u> , 12(3):233-239 (2000).
100.	Wagtmann, N., "gp49: An Ig-like Receptor with Inhibitory Properties on Mast Cells and Natural Killer Cells," <u>Current Top. Microbial. Immunol.</u> , 244:107-113 (1999).
101.	Wallace, R. B. et al., "Oligonucleotide Probes for the Screening of Recombinant DNA Libraries," <u>Methods Enzymol.</u> , 152:432-441 (1987).
102.	Warren, K. G. et al., "Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B-cell epitope and a model of its features," <u>Proc. Natl. Acad. Sci. USA</u> , 92:11061-11065 (1995).
103.	Warren, K. G. et al., "Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis," <u>J. Neuroimmunol.</u> , 43:87-96 (1993).
104.	Warren, K. G. et al., "Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid," <u>J. Neuroimmunol.</u> , 39:81-90 (1992).
105.	Warren, K. G. et al., "Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P ₈₅ VVHFFKNIVTP ₉₆ in chronic progressive multiple sclerosis," <u>J. Neurol. Sci.</u> , 152:31-38 (1997).
106.	Watson, J. L. et al., "Molecular cloning and sequencing of the low-affinity IgE receptor (CD23) for horse and cattle," <u>Vet. Immunol. Immunopathol.</u> , 73:323-329 (2000).
107.	Watts, C., "Antigen processing in the endocytic compartment," <u>Curr. Opin. Immunol.</u> , 13:(1):26-31 (2001).
108.	Watts, C., "Capture and Processing of Exogenous Antigens for Presentation on MHC Molecules," <u>Annu. Rev. Immunol.</u> , 15:821-850 (1997).
109.	Weiner, H. L., "Oral Tolerance for the Treatment of Autoimmune Diseases," <u>Annu. Rev. Med.</u> , 48:341-351 (1997).
110.	Wetmur, J. G. et al., "Kinetics of Renaturation of DNA," <u>J. Mol. Biol.</u> , 31:349-370 (1968).
111.	Wetmur, J. G., "DNA Probes: Applications of the Principles of Nucleic Acid Hybridization," <u>Critical Reviews in Biochemistry and Molecular Biology</u> , 26(3/4):227-259 (1991).
112.	Wines, B. D. et al., "The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors Fc _y RI and Fc _y RIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A," <u>J. Immunol.</u> , 164(10):5313-5318 (2000).
113.	Wucherpfennig, K. W. et al., "Recognition of the Immunodominant Myelin Basic Protein Peptide by Autoantibodies and HLA-DR2-restricted T Cell Clones from Multiple Sclerosis Patients," <u>J. Clin. Invest.</u> , 100(5):1114-1122 (1997).
114.	Yarden, Y. et al., "Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand," <u>EMBO J.</u> , 6(11):3341-51 (1987).
115.	Zhang, Z. et al., "Two Unusual Forms of Human Immunoglobulin E Encoded by Alternative RNA splicing of ε Heavy Chain Membrane Exons," <u>The Journal of Experimental Med.</u> , 176:233-243 (July 1992).

W:\DOCS\EJD\UC067.004A\EJD-1034.DOC - 012502

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	